| __timestamp | Amphastar Pharmaceuticals, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 5078000000 |
| Thursday, January 1, 2015 | 46974000 | 4717000000 |
| Friday, January 1, 2016 | 47298000 | 5096000000 |
| Sunday, January 1, 2017 | 50918000 | 4986000000 |
| Monday, January 1, 2018 | 58044000 | 4214000000 |
| Tuesday, January 1, 2019 | 63109000 | 3806000000 |
| Wednesday, January 1, 2020 | 65157000 | 3671000000 |
| Friday, January 1, 2021 | 68920000 | 3528000000 |
| Saturday, January 1, 2022 | 66592000 | 3445000000 |
| Sunday, January 1, 2023 | 80393000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry players: Teva Pharmaceutical Industries Limited and Amphastar Pharmaceuticals, Inc., from 2014 to 2023. Over this period, Teva's SG&A expenses have seen a significant decline, dropping by approximately 31% from 2014 to 2023. In contrast, Amphastar's expenses have surged by nearly 99%, reflecting a strategic expansion or increased operational costs. Notably, Teva's expenses, despite the reduction, remain substantially higher, averaging around 70 times more than Amphastar's. This disparity highlights the scale and operational differences between the two companies. As the pharmaceutical sector continues to face challenges and opportunities, understanding these financial dynamics is crucial for stakeholders and investors.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Breaking Down SG&A Expenses: argenx SE vs Teva Pharmaceutical Industries Limited
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and CRISPR Therapeutics AG
Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
Alkermes plc vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Vericel Corporation vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.